LSKB Announces that Enrollment has Opened at Huntsman Cancer Institute for the APPEASE Study combining Rivoceranib and Pembrolizumab
SALT LAKE CITY, USA, June 19, 2018 -- LSK BioPharma (LSKB, Company) announced that enrollment has opened for the APPEASE study, “A phase 1/2 open label study of the safety and efficacy of apatinib [rivoceranib] administered to patients with advanced